EA201890981A1 - Новые гетероциклические антиэстрогены - Google Patents

Новые гетероциклические антиэстрогены

Info

Publication number
EA201890981A1
EA201890981A1 EA201890981A EA201890981A EA201890981A1 EA 201890981 A1 EA201890981 A1 EA 201890981A1 EA 201890981 A EA201890981 A EA 201890981A EA 201890981 A EA201890981 A EA 201890981A EA 201890981 A1 EA201890981 A1 EA 201890981A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antiestrogens
new heterocyclic
heterocyclic
new
suppressors
Prior art date
Application number
EA201890981A
Other languages
English (en)
Other versions
EA034131B1 (ru
Inventor
Ранджан Кумар Паль
Амит Правинбхай Седани
Каушиккумар Дханджибхай Праджапати
Диджикса Пинакин Рана
Сандип Панкаджбхай Патхак
Джапан Нитинкумар Десай
Джайрадж Дилипбхай Арадхие
Бхавеш Моханбхай Панчал
Индранил Гхош
Тринадха Рао Читтури
Original Assignee
Сан Фарма Адвансед Ресёрч Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресёрч Компани Лимитед filed Critical Сан Фарма Адвансед Ресёрч Компани Лимитед
Publication of EA201890981A1 publication Critical patent/EA201890981A1/ru
Publication of EA034131B1 publication Critical patent/EA034131B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

В настоящем изобретении представлены новые гетероциклические соединения в качестве противораковых средств, в частности антагонистов/супрессоров рецептора эстрогена (ER), и способ их получения.
EA201890981A 2015-10-27 2016-10-26 Гетероциклические антиэстрогены EA034131B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4058MU2015 2015-10-27
PCT/IN2016/050364 WO2017072792A1 (en) 2015-10-27 2016-10-26 Novel heterocyclic antiestrogens

Publications (2)

Publication Number Publication Date
EA201890981A1 true EA201890981A1 (ru) 2018-09-28
EA034131B1 EA034131B1 (ru) 2020-01-09

Family

ID=58629986

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890981A EA034131B1 (ru) 2015-10-27 2016-10-26 Гетероциклические антиэстрогены

Country Status (26)

Country Link
US (2) US10865199B2 (ru)
EP (2) EP4043438A1 (ru)
JP (2) JP6855475B2 (ru)
KR (1) KR20180088375A (ru)
CN (1) CN108699021B (ru)
AU (1) AU2016347679B2 (ru)
BR (1) BR112018008375B1 (ru)
CA (1) CA3001958A1 (ru)
DK (1) DK3368519T3 (ru)
EA (1) EA034131B1 (ru)
ES (1) ES2916223T3 (ru)
HR (1) HRP20220640T1 (ru)
HU (1) HUE059386T2 (ru)
IL (2) IL283559B (ru)
LT (1) LT3368519T (ru)
MX (1) MX2018005305A (ru)
PH (1) PH12018500829A1 (ru)
PL (1) PL3368519T3 (ru)
PT (1) PT3368519T (ru)
RS (1) RS63217B1 (ru)
SA (1) SA518391423B1 (ru)
SG (2) SG11201803119XA (ru)
SI (1) SI3368519T1 (ru)
UA (1) UA122348C2 (ru)
WO (1) WO2017072792A1 (ru)
ZA (1) ZA201802615B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803119XA (en) * 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens
AU2016366680B2 (en) 2015-12-09 2021-06-24 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN110177554B (zh) 2017-01-06 2023-06-02 G1治疗公司 用于治疗癌症的组合疗法
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
KR20220046586A (ko) 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) * 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2004091488A2 (en) * 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
EP1846397A1 (en) * 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ES2627692T3 (es) * 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
EP3010501B1 (en) 2013-06-19 2021-11-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2014203132A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
SG11201803119XA (en) * 2015-10-27 2018-05-30 Sun Pharma Advanced Res Co Ltd Novel heterocyclic antiestrogens

Also Published As

Publication number Publication date
BR112018008375B1 (pt) 2023-12-12
JP7052111B2 (ja) 2022-04-11
PL3368519T3 (pl) 2022-06-06
JP2018536647A (ja) 2018-12-13
SG11201803119XA (en) 2018-05-30
JP2021098749A (ja) 2021-07-01
AU2016347679B2 (en) 2020-06-25
US20210053947A1 (en) 2021-02-25
HRP20220640T1 (hr) 2022-07-08
WO2017072792A1 (en) 2017-05-04
PT3368519T (pt) 2022-05-25
ZA201802615B (en) 2022-10-26
SG10201913001SA (en) 2020-03-30
IL258949B (en) 2021-06-30
KR20180088375A (ko) 2018-08-03
MX2018005305A (es) 2019-04-29
IL258949A (en) 2018-06-28
US10865199B2 (en) 2020-12-15
DK3368519T3 (da) 2022-05-23
CA3001958A1 (en) 2017-05-04
IL283559A (en) 2021-07-29
US11465990B2 (en) 2022-10-11
RS63217B1 (sr) 2022-06-30
PH12018500829A1 (en) 2018-10-15
EA034131B1 (ru) 2020-01-09
US20180354936A1 (en) 2018-12-13
LT3368519T (lt) 2022-06-10
ES2916223T3 (es) 2022-06-29
JP6855475B2 (ja) 2021-04-07
EP3368519A4 (en) 2019-04-10
SA518391423B1 (ar) 2021-03-31
EP3368519B1 (en) 2022-04-06
IL283559B (en) 2022-07-01
EP3368519A1 (en) 2018-09-05
UA122348C2 (uk) 2020-10-26
CN108699021A (zh) 2018-10-23
EP4043438A1 (en) 2022-08-17
BR112018008375A2 (pt) 2018-10-23
AU2016347679A1 (en) 2018-05-10
CN108699021B (zh) 2022-10-04
SI3368519T1 (sl) 2022-07-29
HUE059386T2 (hu) 2022-11-28

Similar Documents

Publication Publication Date Title
EA201890981A1 (ru) Новые гетероциклические антиэстрогены
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CR20160419A (es) Nuevos compuestos biciclicos
MX2019011911A (es) Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
HK1253023A1 (zh) 作為nr2bnmda受體拮抗劑的3，3-二氟哌啶氨基甲酸酯雜環化合物
CL2015002358A1 (es) Compuestos bicíclicos.
EA201591709A1 (ru) 5-бром-индирубины
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
EA201691493A1 (ru) Замещенные n-арилпиридиноны
LT3625221T (lt) 3-metilpirolidin-2,5-diono dariniai, naudotini kaip cgrp receptoriaus antagonistai
MX2017010526A (es) Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas.
EA201790482A1 (ru) Модифицированные полипептиды vip3
PH12017501214A1 (en) Cgrp antagonist peptides
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
HK1257896B (zh) 作為trpm8拮抗劑的(4-羥基-2-苯基-1，3-噻唑-5-基)甲酮衍生物
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6
DK3490535T3 (da) Depotsammensætning, der omfatter mikroniseret tolcapon
TH1601003731A (th) สารประกอบไทรไซคลิกเป็นสารต้านมะเร็ง